Clinical Evidence of Nasal High-Flow Therapy in Chronic Obstructive Pulmonary Disease PatientsElshof, J. & Duiverman, M. L., 2020, In : Respiration. 99, 2, p. 140-153 14 p.
Research output: Contribution to journal › Review article › Academic › peer-review
Nasal high-flow therapy (NHFT) is an upcoming treatment for chronic obstructive pulmonary disease (COPD) patients. It supplies heated, humidified, and, desirably, oxygen-enriched air through a nasal cannula at flow rates up to 60 L/min. Several studies examined the effect of NHFT in COPD patients, but a clear overview is lacking. The present review aimed to give an overview of the clinical evidence of NHFT in 3 aspects of COPD care: long-term use in stable COPD patients, use for treatment of COPD exacerbations, and use during exercise therapy in COPD. For each topic, a specific literature search was performed up to December 9, 2019. Studies show promising results, with most evidence for its long-term use in hypoxemic COPD patients that frequently exacerbate, and very limited evidence for its use during COPD exacerbations or as a worthwhile adjunct to exercise training. More evidence is therefore needed to know how to incorporate NHFT in standard clinical practice.
|Number of pages||14|
|Early online date||28-Jan-2020|
|Publication status||Published - 2020|
- Nasal high-flow therapy, Chronic obstructive pulmonary disease, Long-term treatment, Exacerbation, Exercise training, POSITIVE-PRESSURE VENTILATION, HYPERCAPNIC RESPIRATORY-FAILURE, TERM HUMIDIFICATION THERAPY, CANNULA OXYGEN-THERAPY, NONINVASIVE VENTILATION, COPD PATIENTS, EXERCISE, EXACERBATIONS, MULTICENTER, EFFICACY